Oncodesign Services, a leading Contract Research Organization specialized in drug discovery and preclinical services in oncology and immuno-inflammation, has executed a Preclinical License and Supply Agreement with ImaginAb for the use of their investigational CD8 ImmunoPET (89Zr crefmirlimab berdoxam) technology. ImaginAb, a biotechnology company, developed CD8 ImmunoPET, a 89Zr PET imaging agent to enable the whole body visualization of the immune system, particularly in patients undergoing immunotherapy or radiopharmaceutical therapies.
By using this cutting-edge imaging technology in preclinical studies, Oncodesign Services’ team hopes to gain insights of the predictive effectiveness of novel treatment approaches in immunotherapy and radioimmunotherapy, particularly in the context of cancer.
Fabrice Viviani, President & CEO of Oncodesign Services, said: “We are pleased to integrate this groundbreaking technology in our portfolio. The CD8 ImmunoPET offering will enhance our services and bridge the gap between preclinical and clinical stages. We hope to be able to better track the efficacy of novel immunotherapies and propose a dynamic follow-up of immune T CD8 cells into our preclinical models. Ultimately, it will enable us to improve our knowledge in the era of personalized medicine.”
Ian Wilson, Chief Executive Officer of ImaginAb, commented: “We believe this partnership will benefit pharma and biotech companies, allowing them to utilize our investigational imaging agent with the aim to improve understanding of the potential efficacy of their pipeline therapeutic products in preclinical studies.”
For more information, visit: www.oncodesign-services.com/
Digital issue: Please click here for more information